AUG 20, 2026 · PHASE 3 TRIAL
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
ClinicalTrials.gov
This is a Phase 3 trial registration with no posted results; the study is actively recruiting and outcomes have not yet been reported.
Reported
Planned sample size586
Primary endpoint 1Change from baseline in ADAS-Cog11 at week…
Primary endpoint 2CIBIC+ at week 24